ABSTRACT
BACKGOUND: In recent years we have witnessed an increase in infections due to multidrug-resistant organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014 we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g. METHODS: We compared bacterial infections and their resistance phenotype during the first post-transplant month with an historical cohort collected during 2013 that had received Cefazolin. RESULTS: During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR 0.16, 95%CI: 0.03-0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1-22.6) and acute rejection (HR 14.5, 95% CI: 1.3-162) were associated to ESBL- producing Enterobacteriaceae infection. CONCLUSIONS: Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without increasing the incidence of other multidrug-resistant microorganisms or C. difficile.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Cefazolin/therapeutic use , Enterobacteriaceae Infections/prevention & control , Ertapenem/therapeutic use , Postoperative Complications/prevention & control , Adult , Aged , Enterobacteriaceae/enzymology , Enterobacteriaceae Infections/microbiology , Female , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , beta-Lactam ResistanceABSTRACT
The aim of the present study was to determine the clinical characteristics, frequency of opportunistic infections (OI) in HCV-positive kidney recipients, and to evaluate HCV replication as a risk factor for developing an OI. We conducted a retrospective study of all kidney recipients from 2003 to 2014. A total of 1203 kidney transplants were performed during the study period. Opportunistic infections were recorded in 251 patients (21%) and nucleic acid amplification testing (NAAT) positivity in 75 (6%). Patients who are HCV NAAT positive were more likely to present an OI than those who are HCV NAAT negative (45% vs 20%, P < 0.001). Multivariate analysis showed the factors that were independently associated with the development of OI to be acute rejection, graft loss, post-transplantation hemodialysis, and HCV replication. Liver cirrhosis after transplantation could not be considered a risk factor to develop OI. To conclude, a high index of suspicion of OI must be maintained in the case of kidney recipients with HCV replication. Active surveillance of cytomegalovirus infection and other prophylactic strategies against OI should be considered after 6 month post-transplantation. Prompt initiation of DAA therapies may be a useful option aiming to decrease the incidence of OI after transplantation.
Subject(s)
Graft Rejection/etiology , Hepatitis C, Chronic/complications , Kidney Transplantation/adverse effects , Opportunistic Infections/etiology , Viremia/complications , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Graft Rejection/pathology , Graft Survival , Hepacivirus/isolation & purification , Hepatitis C, Chronic/virology , Humans , Male , Middle Aged , Opportunistic Infections/pathology , Postoperative Complications , Prognosis , Retrospective Studies , Risk Factors , Survival Rate , Transplant Recipients , Viremia/virology , Young AdultABSTRACT
We aimed to determine the epidemiology, risk factors, and impact of bacterial infection on pancreatic function after pancreas transplantation. Data for pancreas transplant recipients were retrospectively reviewed between 2000 and 2014 for at least 1 year. We collected and analyzed post-transplant data for bacterial infection, morbidity, and mortality. During the study period, 312 pancreas transplants were performed. In total, 509 episodes of bacterial infection were diagnosed in 191 patients (61%). Multidrug-resistant (MDR) organisms were present in 173 of the 513 isolated microorganisms (33%). Risk factors independently associated with bacterial infection were acute allograft rejection (OR 1.7, 95%CI 1.1-3), the need for post-transplant hemodialysis, (OR 5.3, 95%CI 1.8-15.7) and surgical re-intervention (OR 2.8, 95%CI 1.5-5.1), which was also considered a risk factor for infections caused by MDR bacteria. Graft survival was associated with the occurrence of one or more episodes of bacterial infection (log-rank test = 0.009). Surgical re-intervention was independently associated with graft loss (OR 2.5, 95%CI 1.3-4.7). To conclude, pancreas recipients frequently experienced bacterial infections associated with the need for hemodialysis or surgical re-intervention. Infection by MDR organisms is a growing concern in these patients and was related to graft survival. Graft loss was independently associated with surgical re-intervention.
Subject(s)
Bacterial Infections/epidemiology , Graft Rejection/epidemiology , Graft Survival , Pancreas Transplantation/adverse effects , Postoperative Complications/epidemiology , Adolescent , Adult , Bacterial Infections/complications , Bacterial Infections/microbiology , Drug Resistance, Multiple, Bacterial , Female , Follow-Up Studies , Graft Rejection/complications , Graft Rejection/microbiology , Humans , Incidence , Male , Middle Aged , Postoperative Complications/microbiology , Prognosis , Prospective Studies , Retrospective Studies , Risk Factors , Spain/epidemiology , Young AdultABSTRACT
Mammalian target of rapamycin inhibitors (mTORi) prevents cytomegalovirus (CMV) infection in kidney transplant (KT) patients. From May 2010 to December 2013, all KT recipients were retrospectively analysed. Maintenance immunosuppression regimen was divided into mTORi or calcineurin inhibitors (CNI)-based regimen. Since June 2011, CMV-seropositive recipients (R+) treated with high-intensity immunosuppression and mTORi did not receive anti-CMV prophylaxis. We analysed 350 consecutive patients, of which 95 (27%) received mTORi and 255 (73%) CNI-based immunosuppression. A Cox-regression multivariate analysis showed that the use of mTORi-based immunosuppression during all follow-up reduced the risk of CMV infection (HR 0.36, 95% CI 0.15-0.89, P = 0.028) and confirmed in a propensity score-matched cohort (HR 0.4, 95% CI 0.1-0.9, P = 0.047). Early discontinuation of mTORi increased the risk of CMV infection (HR 3.2; 95% CI 1.7-6.0) in univariate analysis. The incidence of CMV infection was not higher among CMV R+ patients on mTORi and requiring high-intensity immunosuppression when CMV prophylaxis was not given. The use of mTORi protected for CMV infection in KT patients, allowing to avoid antiviral prophylaxis for R+ patients receiving high-intensity immunosuppression. The increased risk of CMV infection after early discontinuation of mTORi warrants further research.
Subject(s)
Antilymphocyte Serum/therapeutic use , Cytomegalovirus Infections/prevention & control , Kidney Transplantation , Renal Insufficiency/surgery , TOR Serine-Threonine Kinases/antagonists & inhibitors , Adult , Aged , Calcineurin Inhibitors/therapeutic use , Cytomegalovirus Infections/drug therapy , Female , Humans , Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Multivariate Analysis , Propensity Score , Proportional Hazards Models , Retrospective Studies , Risk , Sirolimus/therapeutic use , SpainABSTRACT
Candida peritonitis is a potentially life-threatening infection after abdominal transplantation, although there is scant information regarding its incidence and outcome. We analysed the incidence rate and outcome of Candida peritonitis in 717 liver or pancreas transplant recipients. Five cases of Candida peritonitis were diagnosed, representing the second most frequent cause of invasive fungal infection in the cohort. The incidence rate of Candida peritonitis during the first 30 days after transplantation was 6.5 cases/10 000 transplant days in pancreas recipients and 1.2 cases/10 000 transplant days in liver recipients (P = 0.035). Four of the five patients received an echinocandin in combination with other antifungal. All patients were alive and with good graft function at 1-year follow-up. In our series, Candida peritonitis in liver and pancreas transplant recipients was not uncommon and had a good prognosis.
Subject(s)
Candidiasis/epidemiology , Liver Transplantation/adverse effects , Pancreas Transplantation/adverse effects , Postoperative Complications/epidemiology , Adult , Aged , Antifungal Agents/therapeutic use , Candida , Candidiasis/drug therapy , Candidiasis/etiology , Candidiasis/microbiology , Cohort Studies , Female , Humans , Male , Middle Aged , Peritonitis/drug therapy , Peritonitis/epidemiology , Peritonitis/etiology , Peritonitis/microbiology , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Postoperative Complications/microbiology , Prospective StudiesABSTRACT
Several genetic polymorphisms of the innate immune system have been described to increase the risk of cytomegalovirus (CMV) infection in transplant patients. The aim of this study was to assess the impact of a polygenic score to predict CMV infection and disease in high risk CMV transplant recipients (heart, liver, kidney or pancreas). On hundred and sixteen CMV-seronegative recipients of grafts from CMV-seropositive donors undergoing heart, liver, and kidney or pancreas transplantation from 7 centres were prospectively included for this purpose during a 2-year period. All recipients received 100-day prophylaxis with valganciclovir. CMV infection occurred in 61 patients (53%) at 163 median days from transplant, 33 asymptomatic replication (28%) and 28 CMV disease (24%). Eleven patients (9%) had recurrent CMV infection. Clinically and/or functionally relevant single nucleotide polymorphisms (SNPs) from TLR2, TLR3, TLR4, TLR7, TLR9, AIM2, MBL2, IL28, IFI16, MYD88, IRAK2 and IRAK4 were assessed by real time polymerase chain reaction (RT-PCR) or sequence-based typing (PCR-SBT). A polygenic score including the TLR4 (rs4986790/rs4986791), TLR9 (rs3775291), TLR3 (rs3775296), AIM2 (rs855873), TLR7 (rs179008), MBL (OO/OA/XAO), IFNL3/IL28B (rs12979860) and IFI16 (rs6940) SNPs was built based on the risk of CMV infection and disease. The CMV score predicted the risk of CMV disease with an AUC of the model of 0.68, with sensitivity and specificity of 64.3 and 71.6%, respectively. Even though further studies are needed to validate this score, its use would represent an effective model to develop more robust scores predicting the risk of CMV disease in donor/recipient mismatch (D+/R-) transplant recipients.
Subject(s)
Cytomegalovirus Infections , Mannose-Binding Lectin , Antiviral Agents/therapeutic use , Cytomegalovirus Infections/prevention & control , Ganciclovir/therapeutic use , Humans , Immunity, Innate , Prospective Studies , Toll-Like Receptor 3 , Toll-Like Receptor 4 , Toll-Like Receptor 7 , Toll-Like Receptor 9 , Transplant RecipientsABSTRACT
Toxoplasmosis after solid organ transplantation is a complication associated with high morbidity and mortality. Universal prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) is effective to prevent post-transplant toxoplasmosis. We report two cases of renal transplant recipients with negative antibodies against Toxoplasma gondii pretransplant who developed toxoplasmosis after TMP-SMX discontinuation. We have also performed a review of published cases of primary toxoplasmosis after renal transplantation. Of 20 cases reviewed, 11 were male and the mean age was 37.8 years (SD = 13.8). Donor serology for T. gondii was determined in 15 donors, two of them (13%) with negative immunoglobulin (Ig)G and four (27%) with positive IgG and IgM antibodies. Fever was present in 85% of primary toxoplasmosis and hematologic abnormalities were observed in 69% of the cases. Ten patients died (50%). All patients with fatal outcomes had clinical evidence of toxoplasmosis during the early post-transplant period (first 90 days), while no patient with late toxoplasmosis died (P = 0.003). Primary toxoplasmosis is associated with high mortality rates and TMP-SMX prophylaxis can delay the onset of symptoms resulting in an improvement of prognosis.
Subject(s)
Kidney Transplantation/adverse effects , Toxoplasmosis/prevention & control , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Adolescent , Adult , Antibodies, Protozoan/analysis , Atovaquone/therapeutic use , Female , Humans , Immunoglobulin M/analysis , Male , Middle Aged , Tissue Donors , Toxoplasma/immunology , Toxoplasmosis/drug therapyABSTRACT
BACKGROUND: Daptomycin is an optimal choice for outpatient parenteral antibiotic therapy (OPAT) because of its safety, once-daily administration and its activity against Gram-positive bacteria. Although daptomycin is increasingly being used in OPAT, limited information about its safety in this scenario is available. METHODS: We performed a prospective multicentre pilot study to evaluate the safety of daptomycin in outpatients with proved or suspected Gram-positive infections (DAPTODOM). The primary objective was to evaluate the safety and the secondary objective to evaluate the efficacy in OPAT. We also looked at the development of daptomycin resistance in those cases with microbiological failure. RESULTS: We included 54 patients from 12 Spanish hospitals, 67% male with a mean age of 67.1 years. Most patients (87%) had chronic underlying diseases. The main reason for inclusion was skin and soft-tissue infections in 52%, followed by bacteremia or endocarditis in 34%. Staphylococcus aureus accounted for 44% of the isolates (24% were methicillin-resistant), coagulase-negative staphylococci 15% and enterococci 7%. Two patients (4%) had to be readmitted because of complications; only one patient had an adverse effect related to daptomycin (increase in serum creatine kinase levels), which disappeared after discontinuation (2%). At the end of follow-up, 96% of patients had good outcome and only 4% of patients did not have a clinical or microbiological cure. The use of a 2-minute bolus in 18 cases was not associated with adverse effects. CONCLUSIONS: Daptomycin was safe and efficacious in outpatients with Gram-positive bacterial infections and can be administered in 2-minute bolus infusion.
Subject(s)
Ambulatory Care/methods , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Daptomycin/administration & dosage , Daptomycin/adverse effects , Gram-Positive Bacterial Infections/drug therapy , Administration, Intravenous/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Outpatients , Pilot Projects , Prospective Studies , Spain , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Current guidelines recommend that treatment of resistant cytomegalovirus (CMV) in solid organ transplant (SOT) recipients must be based on genotypic analysis. However, this recommendation is not systematically followed. OBJECTIVES: To assess the presence of mutations associated with CMV resistance in SOT recipients with suspected resistance, their associated risk factors and the clinical impact of resistance. STUDY DESIGN: Using Sanger sequencing we prospectively assessed the presence of resistance mutations in a nation-wide prospective study between September 2013-August 2015. RESULTS: Of 39 patients studied, 9 (23%) showed resistance mutations. All had one mutation in the UL 97 gene and two also had one mutation in the UL54 gene. Resistance mutations were more frequent in lung transplant recipients (44% p=0.0068) and in patients receiving prophylaxis ≥6 months (57% vs. 17%, p=0.0180). The mean time between transplantation and suspicion of resistance was longer in patients with mutations (239 vs. 100days, respectively, p=0.0046) as was the median treatment duration before suspicion (45 vs. 16days, p=0.0081). There were no significant differences according to the treatment strategies or the mean CMV load at the time of suspicion. Of note, resistance-associated mutations appeared in one patient during CMV prophylaxis and also in a seropositive organ recipient. Incomplete suppression of CMV was more frequent in patients with confirmed resistance. CONCLUSIONS: Our study confirms the need to assess CMV resistance mutations in any patient with criteria of suspected clinical resistance. Early confirmation of the presence of resistance mutations is essential to optimize the management of these patients.
Subject(s)
Cytomegalovirus Infections/virology , Cytomegalovirus/genetics , Drug Resistance, Viral , Genotype , Mutation , Transplant Recipients , Transplants , Adult , Aged , Cytomegalovirus/isolation & purification , DNA, Viral/chemistry , DNA, Viral/genetics , Female , Humans , Male , Middle Aged , Prospective Studies , Sequence Analysis, DNAABSTRACT
BACKGROUND: The incidence of candidemia due to non-Candida albicans Candida species has been progressively increasing in recent years. The use of fluconazole as antifungal prophylaxis has been described as a risk factor for the development of infections by fluconazole resistant Candida strains. We report a case of Candida norvegensis bloodstream infection in a liver transplant recipient. CASE REPORT: A 61-year-old man, who received a third liver allograft and became worse with the onset of ischemic cholangiopathy and recurrent episodes of cholangitis, was admitted to our hospital due to the development of intra-abdominal abscesses. He received multiple antibiotic schemes, and after 3 months he was discharged, maintaining parenteral antibiotic at home. While he was on fluconazole prophylaxis, a breakthrough candidemia due to C. norvegensis occurred. In vitro susceptibilities of the isolate to several antifungal agents were as follows: amphotericin B MIC 0.5 mg/l, flucytosine 64 mg/l, fluconazole 64 mg/l, itraconazole 4 mg/l, voriconazole 0.75 mg/l, and caspofungin 0.047 mg/l. He was treated with anidulafungin with resolution of candidemia. CONCLUSIONS: The use of fluconazole for antifungal prophylaxis may lead to the emergence of fluconazole-resistant Candida infections, with C. norvegensis being a possible emerging pathogen in organ transplant recipients.
Subject(s)
Candida/isolation & purification , Candidemia/microbiology , Candidiasis, Invasive/microbiology , Fungemia/microbiology , Liver Transplantation , Postoperative Complications/microbiology , Abdominal Abscess/drug therapy , Abdominal Abscess/microbiology , Anidulafungin , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Bacterial Infections/complications , Candida/classification , Candida/drug effects , Candidemia/drug therapy , Candidiasis, Invasive/drug therapy , Cholangitis/complications , Communicable Diseases, Emerging/microbiology , Drug Resistance, Multiple, Fungal , Echinocandins/therapeutic use , Fluconazole/adverse effects , Fluconazole/therapeutic use , Fungemia/drug therapy , Gallbladder/blood supply , Humans , Ischemia/complications , Liver Abscess/complications , Liver Abscess/microbiology , Male , Middle Aged , Postoperative Complications/drug therapy , Reoperation , SuperinfectionABSTRACT
Infection is the leading cause of complication after liver transplantation, causing morbidity and mortality in the first months after surgery. Allograft rejection is mediated through adaptive immunological responses, and thus immunosuppressive therapy is necessary after transplantation. In this setting, the presence of genetic variants of innate immunity receptors may increase the risk of post-transplant infection, in comparison with patients carrying wild-type alleles. Numerous studies have investigated the role of genetic variants of innate immune receptors and the risk of complication after liver transplantation, but their results are discordant. Toll-like receptors and mannose-binding lectin are arguably the most important studied molecules; however, many other receptors could increase the risk of infection after transplantation. In this article, we review the published studies analyzing the impact of genetic variants in the innate immune system on the development of infectious complications after liver transplantation.
Subject(s)
Communicable Diseases/genetics , Immunity, Innate/genetics , Liver Failure/surgery , Liver Transplantation/adverse effects , Polymorphism, Single Nucleotide , Animals , Communicable Diseases/immunology , Genetic Predisposition to Disease , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/complications , Hepatitis C/genetics , Hepatitis C/immunology , Hepatitis C/virology , Humans , Immunity, Innate/drug effects , Immunosuppressive Agents/adverse effects , Liver Failure/virology , Recurrence , Risk Factors , Treatment Outcome , Virus ActivationABSTRACT
Background: The incidence of candidemia due to non-Candida albicans Candida species has been progressively increasing in recent years. The use of fluconazole as antifungal prophylaxis has been described as a risk factor for the development of infections by fluconazole resistant Candida strains. We report a case of Candida norvegensis bloodstream infection in a liver transplant recipient. Case report: A 61-year-old man, who received a third liver allograft and became worse with the onset of ischemic cholangiopathy and recurrent episodes of cholangitis, was admitted to our hospital due to the development of intra-abdominal abscesses. He received multiple antibiotic schemes, and after 3 months he was discharged, maintaining parenteral antibiotic at home. While he was on fluconazole prophylaxis, a breakthrough candidemia due to C. norvegensis occurred. In vitro susceptibilities of the isolate to several antifungal agents were as follows: amphotericin B MIC 0.5 mg/l, flucytosine 64 mg/l, fluconazole 64 mg/l, itraconazole 4 mg/l, voriconazole 0.75 mg/l, and caspofungin 0.047 mg/l. He was treated with anidulafungin with resolution of candidemia. Conclusions: The use of fluconazole for antifungal prophylaxis may lead to the emergence of fluconazoleresistant Candida infections, with C. norvegensis being a possible emerging pathogen in organ transplant recipients (AU)
Antecedentes: En los últimos años ha aumentado la incidencia de candidemia causada por especies del género Candida distintas de Candida albicans. Se ha descrito el uso de profilaxis antifúngica con fluconazol como factor de riesgo para el desarrollo de infecciones por cepas de Candida resistentes a este antifúngico. Se describe un caso de fungemia por Candida norvegensis en un receptor de un trasplante hepático. Caso clínico: Un varón de 61 años, receptor de un tercer trasplante hepático que se complica con una colangiopatía isquémica y episodios de colangitis de repetición, ingresó en nuestro hospital por presentar abscesos intraabdominales. Recibió múltiples esquemas antibióticos y, tras 3 meses de ingreso, se dio de alta manteniendo un tratamiento antibiótico parenteral en domicilio. Mientras recibía pro- filaxis con fluconazol, desarrolló una candidemia de brecha por C. norvegensis. Los valores de CMI in vitro del aislamiento para algunos antifúngicos fueron los siguientes: anfotericina B 0,5 mg/l, flucitosina 64 mg/l, fluconazol 64 mg/l, itraconazol 4 mg/l, voriconazol 0,75 mg/l y caspofungina 0,047 mg/l. El paciente recibió tratamiento con anidulafungina, con resolución de la candidemia. Conclusiones: El uso de fluconazol como profilaxis antifúngica puede conllevar la aparición de infecciones por especies de Candida resistentes a este antifúngico, siendo C. norvegensis un posible patógeno emergente en pacientes receptores de un órgano sólido (AU)
Subject(s)
Humans , Male , Middle Aged , Candida/pathogenicity , Candidemia/complications , Liver Transplantation/adverse effects , Postoperative Complications , Fluconazole/therapeutic use , Cholangitis/physiopathology , Risk FactorsABSTRACT
Objetivo: Describir la experiencia adquirida tras 5 años de realizar formación en reanimación cardiopulmonar básica (RCP-b) a alumnos de enseñanza secundaria obligatoria(ESO), el porcentaje de aprendizaje satisfactorio inmediato y transcurrido un año desde la finalización del programa y los factores asociados a un buen aprendizaje. Método: El programa utilizado para este fin fue el Programa de Reanimació Orientat a Centres dEnsenyament Secundari (PROCES). Se incluyeron a todos los alumnos que han completado el curso desde 2002 a 2007. Como instrumento de medida del aprendizaje satisfactorio se utilizó un test con 10 preguntas teóricas y 10 preguntas prácticas, el cual se contestó antes de realizar el PROCES e inmediatamente y un año después de concluirlo. Se estudió la influencia en el rendimiento de variables independientes relacionadas con el centro (titularidad, renta del barrio en el que se ubica), con el curso(curso curricular en el que se realiza, personal que desarrolla las clases prácticas) y con el alumno (edad, sexo, intención de estudiar ciencias de la salud, asignaturas pendientes de cursos previos y realización previa de un curso de socorrismo).Resultados: Durante estos 5 cursos académicos, han realizado el PROCES 1.501 alumnos. De ellos, 1.128 completaron el test antes y después del PROCES y 428 al cabo de un año. El porcentaje de aprendizaje satisfactorio inmediato fue del 58%, en tanto quela persistencia del mismo al cabo de un año fue del 42%. El estudio multivariado demostró que los centros privados, los centros situados en distritos de baja renta per cápita, el desarrollo del PROCES íntegramente por profesores del centro y la ausencia de asignaturas pendientes de cursos previos por parte del alumno se relacionaron de forma independiente con un mejor rendimiento inmediato, en tanto que sólo los dos últimos factores guardaron una relación significativa con la persistencia del aprendizaje. Conclusión: El PROCES, en manos de médicos especialistas en urgencias y emergencias, es una herramienta excelente para difundir los conocimientos en RCP entre los alumnos de ESO. Su afianzamiento durante los próximos años, así como su incorporación al currículo, pasa necesariamente por una apuesta clara y decidida de las administraciones públicas implicadas (AU)
Objective: To describe 5 years' experience in providing training in basic cardiopulmonary resuscitation (CPR) for students in Spanish obligatory secondary school education, including the percentage of satisfactory learning immediately after training and 1 year later; and to analyze factors associated with satisfactory learning. Methods: The trainers applied the CPR program developed for secondary schools (PROCES). All students who took the course from 2002 through 2007 were included. Learning was assessed with a test containing 10 items on theory and10 on practice; the test was administered immediately before and after the course and again a year later. We also studied the influence of independent variables related to school (public vs private, neighborhood per capita income),course (the grade when the CPR course was taken by a student, instructors giving the practical classes), and student(age, gender, intention to study a health science, courses failed in previous years, and whether a life-saving course had ever been taken).Results: A total of 1501 students took the PROCES course over 5 academic years. The test was taken immediately before and after the course by 1128 students; it was taken again a year later by 428 students. Fifty-eight percent had satisfactory test scores immediately after the course; 42% had satisfactory scores a year later. Multivariate analysis showed that private schools, those in neighborhoods with a low per capita income, those in which the PROCES course was given entirely by instructors belonging to the school, and not carrying failed subjects from previous years were the independent variables associated with better performance just after the course. However, only the last 2 factors were significantly related to maintenance of learning. Conclusion: The PROCES course in the hands of specialists in urgency and emergency medicine is an excellent tool for creating a broader base of CPR knowledge among secondary school students. Maintaining and extending the program over the coming years, as well as integrating it into the school curriculum, are matters that require clear commitment from the relevant public administrations (AU)